Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Director | October 22, 2020 | October 22, 2020 |
| INFINITY PHARMACEUTICALS, INC.INFI · Entity 109802 | Director | January 06, 2017 | January 09, 2017 |
| VARIAN MEDICAL SYSTEMS INCVAR · Entity 140252 | Director | February 09, 2018 | February 12, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Foghorn Therapeutics Inc.
Report date October 22, 2020 · Filed October 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 94,594 |
Reported balance
Holding disclosure · report date 2020-10-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 94,594 |
INFINITY PHARMACEUTICALS, INC.
Report date January 06, 2017 · Filed January 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.46 · Expires 2027-01-06 | Direct | 40,000 |
Reported balance
After 2017-01-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-06 · Grant · Acquired 40,000 · Balance 40,000 F1: The option vests as to 1/8th of the shares on March 31, 2017 and as to 1/8th of the shares at the end of each calendar quarter thereafter, provided that the holder continues to serve as a director of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 1/8th of the shares on March 31, 2017 and as to 1/8th of the shares at the end of each calendar quarter thereafter, provided that the holder continues to serve as a director of the issuer.
VARIAN MEDICAL SYSTEMS INC
Report date February 09, 2018 · Filed February 12, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,441 |
Reported balance
After 2018-02-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-09 · Grant · Acquired 1,441 · Balance 1,441 F1: Each restricted stock unit represents a contingent right to receive one share of VAR common stock. F2: The restricted stock units vest on the earlier of February 9, 2019, or the next Annual Meeting of Stockholders that occurs after the Grant Date. Vested shares will be delivered to the reporting person on vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of VAR common stock.
F2: The restricted stock units vest on the earlier of February 9, 2019, or the next Annual Meeting of Stockholders that occurs after the Grant Date. Vested shares will be delivered to the reporting person on vest date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BRISTOL MYERS SQUIBB CO
Report date September 30, 2018 · Filed October 03, 2018
Section 16 reporting ended · disclosed 2018-10-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security | Direct | 3,680.787 |
Reported balance
After 2018-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-09-30 · Grant · Acquired 385.717 · Balance 3,680.787 F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
F2: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2018 Filed Oct 3, 2018 01:39 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 385.717 | $62.08 | $23,945.31 |
DisclosureSEC source: 0000014272-18-000180 · wf-form4_153853075770752.xml · derivative · entry 1 Baselga Jose · CIK 0001601687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,680.787 Underlying: Common Stock, $0.10 par value · 385.717 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| June 30, 2018 Filed Jul 4, 2018 01:25 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 519.516 | $55.34 | $28,750.02 |
DisclosureSEC source: 0000014272-18-000145 · wf-form4_153066750257052.xml · derivative · entry 1 Baselga Jose · CIK 0001601687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,295.07 Underlying: Common Stock, $0.10 par value · 519.516 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 20:37 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 154.422 | $63.25 | $9,767.19 |
DisclosureSEC source: 0000014272-18-000104 · wf-form4_152278782270219.xml · derivative · entry 1 Baselga Jose · CIK 0001601687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,754.642 Underlying: Common Stock, $0.10 par value · 154.422 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · balance_after: Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:35 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantDeferred Share Units · Derivative | 2,600.22 | $65.69 | $170,808.45 |
DisclosureSEC source: 0000014272-18-000066 · wf-form4_152028571446188.xml · derivative · entry 1 Baselga Jose · CIK 0001601687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600.22 Underlying: Common Stock, $0.10 par value · 2,600.22 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F2 · shares: Represents pro rata portion of the 2018 annual Deferred Share Units awards granted to the Company's directors. F1 · derivative.exercise_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. F1 · derivative.expiration_date: Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 20:15 UTC | VARIAN MEDICAL SYSTEMS INC VAR · Entity 140252 | GrantRestricted Stock Units · Derivative | 1,441 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-005272 · form4.xml · derivative · entry 1 Baselga Jose · CIK 0001601687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,441 Underlying: Common Stock · 1,441 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of VAR common stock. F2 · derivative.exercise_date: The restricted stock units vest on the earlier of February 9, 2019, or the next Annual Meeting of Stockholders that occurs after the Grant Date. Vested shares will be delivered to the reporting person on vest date. F2 · derivative.expiration_date: The restricted stock units vest on the earlier of February 9, 2019, or the next Annual Meeting of Stockholders that occurs after the Grant Date. Vested shares will be delivered to the reporting person on vest date. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 19:57 UTC | VARIAN MEDICAL SYSTEMS INC VAR · Entity 140252 | GrantDeferred Stock Units · Derivative | 1,871 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009889 · form4.xml · derivative · entry 1 Baselga Jose · CIK 0001601687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,871 Underlying: Common Stock · 1,871 shares Expires not disclosed F1 · derivative.exercise_price: Each Deferred Stock Unit represents the right to receive one share of VAR common stock. F2 · derivative.exercise_date: The Deferred Stock Units vest in four equal quarterly installments over a 12 month period beginning March 1, 2017. Vested shares will be delivered to the reporting person on the earlier of three years from the grant date, termination/retirement date, or a change of control. F2 · derivative.expiration_date: The Deferred Stock Units vest in four equal quarterly installments over a 12 month period beginning March 1, 2017. Vested shares will be delivered to the reporting person on the earlier of three years from the grant date, termination/retirement date, or a change of control. Read SEC document |
| January 06, 2017 Filed Jan 9, 2017 16:47 UTC | INFINITY PHARMACEUTICALS, INC. INFI · Entity 109802 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0000899243-17-000805 · doc4.xml · derivative · entry 1 Baselga Jose · CIK 0001601687 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-01-06 F1 · derivative.exercise_date: The option vests as to 1/8th of the shares on March 31, 2017 and as to 1/8th of the shares at the end of each calendar quarter thereafter, provided that the holder continues to serve as a director of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.